674 related articles for article (PubMed ID: 16356796)
21. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
22. PET/CT and choline: diagnosis and staging.
Farsad M; Schwarzenböck S; Krause BJ
Q J Nucl Med Mol Imaging; 2012 Aug; 56(4):343-53. PubMed ID: 23013664
[TBL] [Abstract][Full Text] [Related]
23. Non-invasive assessment of inter-and intrapatient variability of integrin expression in metastasized prostate cancer by PET.
Beer AJ; Schwarzenböck SM; Zantl N; Souvatzoglou M; Maurer T; Watzlowik P; Kessler H; Wester HJ; Schwaiger M; Krause BJ
Oncotarget; 2016 May; 7(19):28151-9. PubMed ID: 27058620
[TBL] [Abstract][Full Text] [Related]
24. Value of 11C-choline PET and contrast-enhanced CT for staging of bladder cancer: correlation with histopathologic findings.
Picchio M; Treiber U; Beer AJ; Metz S; Bössner P; van Randenborgh H; Paul R; Weirich G; Souvatzoglou M; Hartung R; Schwaiger M; Piert M
J Nucl Med; 2006 Jun; 47(6):938-44. PubMed ID: 16741302
[TBL] [Abstract][Full Text] [Related]
25. Positron emission tomography in urologic oncology.
Shvarts O; Han KR; Seltzer M; Pantuck AJ; Belldegrun AS
Cancer Control; 2002; 9(4):335-42. PubMed ID: 12228759
[TBL] [Abstract][Full Text] [Related]
26. Scanning with 18F-FDG-PET/CT for detection of pelvic nodal involvement in inguinal node-positive penile carcinoma.
Graafland NM; Leijte JA; Valdés Olmos RA; Hoefnagel CA; Teertstra HJ; Horenblas S
Eur Urol; 2009 Aug; 56(2):339-45. PubMed ID: 19477581
[TBL] [Abstract][Full Text] [Related]
27. [Diagnostic imaging of the prostate cancer].
Mocarska A; Starosławska E; Iwonna ZC; Brzozowska A; Łosicki M; Stasiewicz D; Burdan F
Pol Merkur Lekarski; 2012 Dec; 33(198):357-63. PubMed ID: 23437709
[TBL] [Abstract][Full Text] [Related]
28. Which metabolic imaging, besides bone scan with 99mTc-phosphonates, for detecting and evaluating bone metastases in prostatic cancer patients? An open discussion.
Bombardieri E; Setti L; Kirienko M; Antunovic L; Guglielmo P; Ciocia G
Q J Nucl Med Mol Imaging; 2015 Dec; 59(4):381-99. PubMed ID: 26337240
[TBL] [Abstract][Full Text] [Related]
29. Recurrent and metastatic breast cancer PET, PET/CT, PET/MRI: FDG and new biomarkers.
Gaeta CM; Vercher-Conejero JL; Sher AC; Kohan A; Rubbert C; Avril N
Q J Nucl Med Mol Imaging; 2013 Dec; 57(4):352-66. PubMed ID: 24322792
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of Prostate Cancer with 11C- and 18F-Choline PET/CT: Diagnosis and Initial Staging.
Nitsch S; Hakenberg OW; Heuschkel M; Dräger D; Hildebrandt G; Krause BJ; Schwarzenböck SM
J Nucl Med; 2016 Oct; 57(Suppl 3):38S-42S. PubMed ID: 27694169
[TBL] [Abstract][Full Text] [Related]
31. Advancement of MR and PET/MR in Prostate Cancer.
Lindenberg L; Ahlman M; Turkbey B; Mena E; Choyke P
Semin Nucl Med; 2016 Nov; 46(6):536-543. PubMed ID: 27825433
[TBL] [Abstract][Full Text] [Related]
32. PET-CT for treatment planning in prostate cancer.
Picchio M; Crivellaro C; Giovacchini G; Gianolli L; Messa C
Q J Nucl Med Mol Imaging; 2009 Apr; 53(2):245-68. PubMed ID: 19293771
[TBL] [Abstract][Full Text] [Related]
33. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
34. Positron emission tomography in gynecologic cancer.
Yen TC; Lai CH
Semin Nucl Med; 2006 Jan; 36(1):93-104. PubMed ID: 16356798
[TBL] [Abstract][Full Text] [Related]
35. PET imaging in adaptive radiotherapy of prostate tumors.
Beuthien-Baumann B; Koerber SA
Q J Nucl Med Mol Imaging; 2018 Dec; 62(4):404-410. PubMed ID: 29869483
[TBL] [Abstract][Full Text] [Related]
36. Detection of Bone Metastases Using 11C-Acetate PET in Patients with Prostate Cancer with Biochemical Recurrence.
Spick C; Polanec SH; Mitterhauser M; Wadsak W; Anner P; Reiterits B; Haug AR; Hacker M; Beheshti M; Karanikas G
Anticancer Res; 2015 Dec; 35(12):6787-91. PubMed ID: 26637897
[TBL] [Abstract][Full Text] [Related]
37. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy.
Schöder H; Herrmann K; Gönen M; Hricak H; Eberhard S; Scardino P; Scher HI; Larson SM
Clin Cancer Res; 2005 Jul; 11(13):4761-9. PubMed ID: 16000572
[TBL] [Abstract][Full Text] [Related]
38. Innovations in imaging modalities for recurrent and metastatic prostate cancer: a systematic review.
Albisinni S; Aoun F; Marcelis Q; Jungels C; Al-Hajj Obeid W; Zanaty M; Tubaro A; Roumeguere T; De Nunzio C
Minerva Urol Nefrol; 2018 Aug; 70(4):347-360. PubMed ID: 29388415
[TBL] [Abstract][Full Text] [Related]
39. Dynamic MRI and CAD vs. choline MRS: where is the detection level for a lesion characterisation in prostate cancer?
Schmuecking M; Boltze C; Geyer H; Salz H; Schilling B; Wendt TG; Kloetzer KH; Marx C
Int J Radiat Biol; 2009 Sep; 85(9):814-24. PubMed ID: 19701842
[TBL] [Abstract][Full Text] [Related]
40. The role of positron emission tomography using carbon-11 and fluorine-18 choline in tumors other than prostate cancer: a systematic review.
Treglia G; Giovannini E; Di Franco D; Calcagni ML; Rufini V; Picchio M; Giordano A
Ann Nucl Med; 2012 Jul; 26(6):451-61. PubMed ID: 22566040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
